-+ 0.00%
-+ 0.00%
-+ 0.00%

Yiming Angko-B announced that the company launched a phase II clinical trial of IMM2510 combined with IMM27M for first-line treatment of patients with advanced hepatocellular carcinoma. The first patient administration was successfully completed to evaluate the initial efficacy and safety of the combination therapy; the phase Ib clinical trial of this combination therapy has determined the recommended phase II dose.

Zhitongcaijing·08/27/2026 13:25:06
Listen to the news
Yiming Angko-B announced that the company launched a phase II clinical trial of IMM2510 combined with IMM27M for first-line treatment of patients with advanced hepatocellular carcinoma. The first patient administration was successfully completed to evaluate the initial efficacy and safety of the combination therapy; the phase Ib clinical trial of this combination therapy has determined the recommended phase II dose.